Not only is CLL heterogeneous in watch and wait, that's also the case after treatment. An analysis of over 2,000 patients from three German CLL Study Group clinical trials has identified that unfit patients developing lymphadenopathy (swelling nodes) have a significantly lower median overall survival (OS) than fit patients or patients that develop increasing absolute lymphocyte counts. The authors concluded that “the results suggest that progression by lymphadenopathy is associated with a less favorable clinical course, in particular in unfit patients with CLL. This might help physicians in managing their patients and researchers in designing future clinical trials.”
The clinical trials included in the evaluation were FCR vs FC, FCR vs BR and obinutuzumab in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil. What we don't know is whether the same pattern is true for those treated with the newer inhibitory treatments.
Yet another reason to maintain/improve our fitness: healthunlocked.com/cllsuppo...
This is an unlocked post